Statistics from Altmetric.com
The current management of antiphospholipid syndrome (APS) centres on attenuating the procoagulant state while balancing the haemorrhagic risks.1 This approach relies mainly on a thromboprophylaxis strategy rather than targeting pathogenic antiphospholipid antibodies (aPL)-mediated pathways.
Herewith, we report the aPL disappearance in three patients with APS associated to systemic lupus erythematous (SLE) while on treatment with belimumab, potentially paving the way for development of new targeted therapies for APS. Belimumab is a monoclonal antibody that works by blocking the B-lymphocyte stimulator and avoiding B-cell activation.2 It is the first biological drug approved for the treatment of autoantibody positive SLE in active phase and it has shown its capability to reduce the antibodies levels, including anti-double stranded-DNA.3 Intriguingly, in murine models of APS in the setting of SLE, belimumab …
SS and ER contributed equally.
Handling editor Josef S Smolen
Contributors ER and SS designed the study, performed data analysis and drafted the manuscript. ER, IC, DR1, MR, DR2 and SS gave a substantial contribution to concept and study design and participated in the interpretation of data. All the authors gave the final approval of the version to be published.
Competing interests None declared.
Patient consent Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.